Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Leukemia Research|May 10, 2006
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cellsSrdan Verstovsek, Francis J Giles, Alfonso Quintás-Cardama, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutationSrdan Verstovsek, Taghi Manshouri, Alfonso Quintás-Cardama, et al.
British Journal of Haematology|July 9, 2002
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndromeSrdan Verstovsek, Elihu Estey, Taghi Manshouri, et al.
Experimental Hematology|May 30, 2007
Imatinib effect on growth and signal transduction in polycythemia veraAmos Gaikwad, Srdan Verstovsek, Donghoon Yoon, et al.
Leukemia Research|June 12, 2017
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosisLucia Masarova, Prithviraj Bose, Naval Daver, et al.
Cancer Science|July 11, 2006
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cellsNada Orsolic, Mirna Golemovic, Alfonso Quintás-Cardama, et al.
Cancer|April 25, 2003
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemiaSrdan Verstovsek, Taghi Manshouri, Franklin O Smith, et al.
Cancer Science|May 17, 2008
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutationTaghi Manshouri, Alfonso Quintás-Cardama, Roberto H Nussenzveig, et al.
Haematologica|October 1, 2016
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosisUri Rozovski, Srdan Verstovsek, Taghi Manshouri, et al.
Blood|July 5, 2017
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuationKate J Newberry, Keyur Patel, Lucia Masarova, et al.
Pageof 9